On Monday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $66.01 which represents a decrease of $-0.59 or -0.89% from the prior close of $66.6. The stock opened at $66.24 ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BioMarin Pharmaceutical (BMRN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...

BioMarin Pharmaceutical ( BMRN -4.44%), a leader in treatments for rare genetic disorders, released its Q3 2024 earnings on ...

BioMarin Pharmaceutical (BMRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...

Thank you for standing by. My name is Bary, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin Pharmaceuticals third-quarter 2024 conference ...

A total of 27 analyst ratings have been received for Biomarin Pharmaceutical, with the consensus rating being Outperform. The average one-year price target stands at $100.85, suggesting a potential 44 ...

On Tuesday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $69.91 which represents a decrease of $-0.22 or -0.31% from the prior close of $70.13. The stock opened at $69.78 ...

Third Quarter 2024 Results Key Financial Results Revenue: US$745.7m (up ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...